Published in

Frontiers Media, Frontiers in Bioengineering and Biotechnology, (9), 2022

DOI: 10.3389/fbioe.2021.797359

Links

Tools

Export citation

Search in Google Scholar

Advances in Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles

Journal article published in 2022 by Dingyu Rao, Defa Huang, Chengpeng Sang, Tianyu Zhong ORCID, Zuxiong Zhang, Zhixian Tang
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Exosomes are tiny vesicles with a double membrane structure that cells produce. They range in diameter from 40 to 150 nm and may contain a variety of biomolecules including proteins and nucleic acids. Exosomes have low toxicity, low immunogenicity, and the ability to encapsulate a wide variety of substances, making them attractive drug delivery vehicles. MSCs secrete large amounts of exosomes and hence serve as an excellent source of exosomes. MSCs-derived exosomes have regenerative and tissue repair functions comparable to MSCs and can circumvent the risks of immune rejection and infection associated with MSC transplantation, indicating that they may be a viable alternative to MSCs’ biological functions. In this review, we summarized the drug delivery methods and advantages of exosomes, as well as the advancement of MSC exosomes as drug carriers. The challenges and prospects of using exosomes as drug delivery vectors are presented.